CorporateInformation.com
 
Company Search:
Advanced Search
 
Featured Products and Services
 
 
Wright Investors Service Perspectives
 
 
 
     
  The Wright Reports site is no longer hosted or operated by Manta. Please review the following:
1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing.
2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com
3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp
4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later) 		 
     
 
 
 
Alkermes, Inc. Company Snapshot
Business Description:
Alkermes, Inc. operates in the Pharmaceutical preparations sector. Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone. In September 2011, the Company started its corporate operations in Ireland. In our complete report available for purchase the company is compared to: Salix Pharmaceuticals, Ltd., Caraco Pharmaceutical Laboratories, Ltd. and K-V Pharmaceutical Company.
   
   
 
  Stock Performance Chart for Alkermes, Inc.
 
  Stock Data: Recent Stock Performance:
  Current Price (10/7/2011): 14.56
(Figures in U.S. Dollars)
1 Week -4.5%   13 Weeks -10.3%  
4 Weeks -25.4%   52 Weeks -8.5%  
 
Alkermes, Inc. Key Data:
  Ticker: Country: UNITED STATES
  Exchanges: NAS Major Industry: Drugs, Cosmetics & Health Care
    Sub Industry: Ethical Drug Manufacturers
  2011 Sales 186,640,000
(Year Ending Jan 2012).		 Employees: 600
  Currency: U.S. Dollars Market Cap: 1,889,116,320
  Fiscal Yr Ends: March Shares Outstanding: 129,747,000
  Share Type: Common Closely Held Shares: 56,832,095
 
 
Featured Products and Services
  
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.